SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: celeryroot.com who wrote (241)5/19/1997 8:06:00 AM
From: tonyt   of 1972
 
Reuters just picked up the press release:

Vical (NASDAQ:VICL) melanoma treatment shows efficacy
============================================================
DENVER, Colo., May 19 (Reuter) - Vical Inc (NASDAQ:VICL) said
that initial Phase II data for its Allovectin-7 shows potential
efficacy in certain patients with advanced melanoma.
Preliminary results from a separate Phase I/II trial
indicated potential efficacy in certain patients with inoperable
head and neck cancer, it said.
The results from both trials were presented Saturday at the
annual meeting of the American Society of Clinical Oncology.
Although all melanoma patients enrolled in the multi-center
Phase II clinical trial with Allovectin-7 had advanced
metastatic disease, initial results further suggest that the
potential treatment may be more effective in patients with
advanced regional disease than in patients with widespread
disease affecting multiple internal organs, the company said.
Allovectin-7 is a gene-based product candidate being studied
in melanoma and other types of cancer.
Multi-center Phase II trials of Allovectin-7 began in
September 1995, studying five different cancer indications in
about 20 patients each.
In October 1996, Vical initiated an additional multi-center
trial in which approximately 40 patients with advanced
metastatic melanoma are currently being enrolled and treated.
Several additional Phase I/II trials are ongoing, studying
Allovectin-7 either alone or in combination with other agents in
various cancer indications.

Copyright 1997, Reuters News Service
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News